You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Baxter
Harvard Business School
Dow
Medtronic
McKinsey

Last Updated: March 2, 2021

DrugPatentWatch Database Preview

Litigation Details for IMMUNEX CORPORATION v. SAMSUNG BIOEPIS CO., LTD. (D.N.J. 2019)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Biologic Drugs cited in IMMUNEX CORPORATION v. SAMSUNG BIOEPIS CO., LTD.

The biologic drugs covered by the patents cited in this case are   Start Trial ,   Start Trial , and   Start Trial .

Details for IMMUNEX CORPORATION v. SAMSUNG BIOEPIS CO., LTD. (D.N.J. 2019)

Date Filed Document No. Description Snippet Link To Document
2019-04-30 1 Complaint “Roche Patents”); and • U.S. Patents Nos. 7,915,225 (“the ’225 Patent”), 8,119,605…United States Patent Nos. 8,063,182 (“the ’182 Patent”), 8,163,522 (“the ’522 Patent”), 7,915,225 (“the ’225…arthritis. The ’225 Patent, the ’605 Patent, and the ’631 Patent (“the Immunex Patents”), owned by Immunex…States Patent Nos. 8,063,182 (“the ’182 Patent”) and 8,163,522 (“the ’522 Patent”) (collectively… Patent”), and 8,722,631 (“the ’631 Patent”) (collectively, “the Immunex Patents”). External link to document
2019-12-22 107 Amended Complaint Immunopathology and Immunity, 4' Edition, 6,201,105 B1 3, 2001 Smith et al. …activities”, Eur, J. Immunol. 20:1167-1174 6,201,105 B1 3, 2001 Smith et al. … U.S. Patent No. 8,063,182 (“the ’182 Patent”), • U.S. Patent No. 8,163,…Roche Patents”), • U.S. Patent No. 6,872,549 (“the ’549 Patent”), … U.S. Patent No. 6,924,124 (“the ’124 Patent”), • U.S. Patent No. 7,157, External link to document
2019-08-05 70 Answer to Complaint . 7,915,225 (“the ’225 patent”), 8,119,605 (“the ’605 patent), and 8,722,631 (“the ’631 patent) (collectively…the “Roche Patents”); and • U.S. Patents Nos. 7,915,225 (“the ’225 Patent”), 8,119,…the ’522 Patent”); 7,915,225 (“the ’225 Patent”); 8,119,605 (“the ’605 Patent”); and 8,722,631 (“the ’…products: U.S. Patent Nos. 8,063,182 (“the ’182 patent”); 8,163,522 (“the ’522 patent”); 7,915,225; 8,119,605… States Patent Nos. 8,063,182 (“the ’182 Patent”), 8,163,522 (“the ’522 Patent”), 7,915,225 (“the ’225 External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
AstraZeneca
Merck
Harvard Business School
Johnson and Johnson
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.